Carcinoma, Non Small Cell Lung Clinical Trial
Official title:
Phase II Study of Vorinostat (SAHA, Zolinza) and Bortezomib (PS341, Velcade) as Third-Line Treatment in Patients With Advanced Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy of vorinostat and bortezomib in the third line treatment of advanced NSCLC, as well as to assess toxicity (including neuropathy) and tolerability of this regimen.
Current treatment for non-small cell lung cancer (NSCLC) remains inadequate. Vorinostat is a novel agent that inhibits the enzymatic activity of histone deacetylases (HDACs). Bortezomib is a small molecule proteasome inhibitor. Preclinical and clinical studies have shown the advantages of combining these two agents in the treatment of NSCLC ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02135211 -
Healthy Directions After Lung Surgery Pilot
|
N/A | |
Completed |
NCT00191230 -
Gemcitabine/Platinum Containing Regimens as Preoperative Chemotherapy for Patients With Non Small Cell Lung Cancer
|
Phase 2 | |
Withdrawn |
NCT01004419 -
Trial of ZD6474 and Faslodex in Non-Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT01671332 -
Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT00905801 -
Computed Tomography (CT) Perfusion Imaging of Lung Cancer
|
N/A | |
Recruiting |
NCT00184964 -
Validation of Coregistered CT-PET Imaging in Determining Tumor Volume and Atelectasis in Patients With Operable Non-Small-Cell Lung Cancer and Tumor Associated Atelectasis
|
N/A | |
Completed |
NCT00191256 -
Efficacy Trial of Gemcitabine Containing Regimens As Preoperative Chemotherapy in Non Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00954278 -
Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer
|
Phase 1 | |
Terminated |
NCT01282151 -
TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer
|
Phase 3 | |
Terminated |
NCT01088906 -
Study of Pemetrexed Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous NSCLC
|
Phase 2 | |
Completed |
NCT00553254 -
Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer
|
Phase 2 | |
Completed |
NCT01469000 -
A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
Withdrawn |
NCT00934076 -
Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung Cancer
|
Phase 1 | |
Terminated |
NCT01891669 -
A Study Of PF-06263507 In Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00160069 -
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00548093 -
PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib
|
Phase 2 |